Drug intelligence / Profile preview

Phen-an-ka-min

Development stage
Unknown
Lead developer
Sinopharm Xingsha
Modality
Small Molecules
Administration
Oral
01

Overview

Phen-an-ka-min is a combination oral tablet developed and manufactured by Sinopharm Xingsha Pharmaceuticals, primarily used for the symptomatic treatment of the common cold and influenza. The formulation contains paracetamol (acetaminophen), chlorpheniramine maleate, and caffeine. Paracetamol provides analgesic and antipyretic effects by inhibiting cyclooxygenase enzymes and reducing prostaglandin synthesis in the central nervous system. Chlorpheniramine is a first-generation antihistamine that competes with histamine for H1 receptor sites, effectively relieving symptoms such as rhinorrhea, sneezing, and watery eyes. Caffeine is included as a central nervous system stimulant to alleviate the drowsiness often caused by chlorpheniramine and to potentially enhance the analgesic efficacy of paracetamol. This product is an established generic medication in the Chinese market.

Brand names
Phen-an-ka-min酚氨咖敏片
Other names
paracetamol + chlorpheniramine + caffeineAcetaminophen, chlorpheniramine, and caffeine tablets
02

Targets

ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)ADORA2A (Adenosine A₂A Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Phen-an-ka-min.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phen-an-ka-min.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call